[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @GilaMonstrum Noumena Analysis Noumena Analysis posts on X about $vktx, $pfe, $mtsr, $lly the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1494036559502401539/interactions)  - X Week XXXXX +20,264% - X Month XXXXXX -XX% - X Months XXXXXXX -XX% - X Year XXXXXXX +167% ### Mentions: X [#](/creator/twitter::1494036559502401539/posts_active)  - X Week XX +267% - X Month XX +26% - X Months XX -XX% - X Year XXX +331% ### Followers: XXXXX [#](/creator/twitter::1494036559502401539/followers)  - X Week XXXXX +2.10% - X Month XXXXX +5.90% - X Months XXXXX +53% - X Year XXXXX +221% ### CreatorRank: XXXXXXX [#](/creator/twitter::1494036559502401539/influencer_rank)  ### Social Influence [#](/creator/twitter::1494036559502401539/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [$vktx](/topic/$vktx) #1, [$pfe](/topic/$pfe), [$mtsr](/topic/$mtsr) #4, [$lly](/topic/$lly), [weight loss](/topic/weight-loss) #853, [rates](/topic/rates) #675, [$nvo](/topic/$nvo), [over the](/topic/over-the), [ans](/topic/ans), [investment](/topic/investment) **Top assets mentioned** [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr) [Eli Lilly and Company (LLY)](/topic/$lly) [Novo-Nordisk (NVO)](/topic/$nvo) [AltLayer (ALT)](/topic/$alt) ### Top Social Posts [#](/creator/twitter::1494036559502401539/posts) --- Top posts by engagements in the last XX hours "@bioinvestor24 $pfe is up $mtsr is up $vktx is down" [X Link](https://x.com/GilaMonstrum/status/1973028385040519444) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-30T14:13Z 1895 followers, XXX engagements "@Doctor_Salomon @LNG_Investor_ My base case: the XX mg arm is at least non-inferior to TZP on weight loss with better safety given the slow titration (starting at XXX mg). I expect the XXXX mg arm to outperform TZP XX mg on both weight loss and safety" [X Link](https://x.com/GilaMonstrum/status/1979961268753629538) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T17:22Z 1928 followers, XXX engagements "@bioinvestor24 I just cant get over the fact that $PFE said they reviewed this data and felt "comfortable". It practically screams shady how can they feel confortable to go against $LLY ans $NVO with this" [X Link](https://x.com/GilaMonstrum/status/1973027948103102943) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-30T14:11Z 1902 followers, 4660 engagements "How would $LLY tirzepatide compare with $VKTX sc VK2735 if both are titrated the same To answer this question I built a PK/PD model using the methodology briefly described below: X. Simulate single dose PK for each drug from published parameters (T1/2 and Tmax are reported in the literature/ corporate decks. F=80% for TZP I assumed the same for VK 2735). X. Convert plasma profiles to cumulative exposure (AUC) using the trapezoidal rule. X. Plot AUC to weight loss data from SURMOUNT-1 and VENTURE. X. Fit an individual Hill model for VK and TZP with an assumed Emax of XX% for both drugs." [X Link](https://x.com/GilaMonstrum/status/1979950271007699262) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T16:38Z 1928 followers, 12.4K engagements "I understand you want to protect your investment but highlighting $VKTX oral VK 2735 d/c while overlooking $ALT challenging obesity d/c rates is a bit funny tbh. VK2735 has oral and sc forms the higher d/c occurred in the P2 oral trial. Pemvis real competitor would be sc VK2735 so.yeah" [X Link](https://x.com/GilaMonstrum/status/1980135515350339800) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-20T04:54Z 1928 followers, 1015 engagements "@GodSaveCharles "Has yet surpassed" as in "to date". I did not make any assumptions on future trials I guess Novo already made that assumption" [X Link](https://x.com/GilaMonstrum/status/1980160040981172520) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-20T06:31Z 1928 followers, XXX engagements "@bioinvestor24 Clinically it seems to be similar to $LLY tirzepatide but the studies are too short (4 weeks). I wasn't impressed by their P2 data vs semaglutide X mg in diabetics. Maybe it is wishful thinking but I am starting to see a pattern here:" [X Link](https://x.com/GilaMonstrum/status/1929625513695297607) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-06-02T19:45Z 1925 followers, 4480 engagements "$MTSR $PFE Finally released the Phase 2b VESPER X and VESPER X results and frankly their PR is confusing and selectively framed. I have a headache after reading it. $VKTX BL take notes this is a masterclass in how to spin your data. Vesper X had X arms (MET-097i XXX mg XXX mg XXX mg and XXX mg) QW without titration. The efficacy they reported is pbo-adjusted and they withheld the actual placebo WL data. This is a huge red flag given that in their previous trials the placebo arm gains weight (uniquely as far as Ive seen - see pic). By hiding placebo here they can inflate the headline and claim" [X Link](https://x.com/GilaMonstrum/status/1972908597232202073) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-30T06:17Z 1930 followers, 15.3K engagements "@Doctor_Salomon @LNG_Investor_ I haven't seen data as good as tzp in Surmount X with anything else so far" [X Link](https://x.com/GilaMonstrum/status/1979957364208840881) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T17:06Z 1930 followers, XXX engagements "Has anyone seen the $MTSR discontinuation rates for any of their drugs $VKTX" [X Link](https://x.com/GilaMonstrum/status/1971189510928322622) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-25T12:26Z 1928 followers, 4589 engagements ""At XX weeks in MOMENTUM mean weight loss reached 1015.6 % without titration and with sub-5 % discontinuations at mid-dose which is extremely impressive for a compound with NO dose escalation" How can you claim sub X% discontinuations with mid doses in Momentum when the XXX mg dose showed a XXXX% d/c and the XXX mg dose showed d/c of XXXX% Also if you include the weight loss of XXXX% for the XXX mg (titrated) dose make sure you also include the d/c rate for that dose (which was a staggering 42.3%). Otherwise it is a WL between XXXX% and XXXX% (8.1% and X% PBO adjusted) at XX weeks with d/c" [X Link](https://x.com/GilaMonstrum/status/1980174877756686376) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-20T07:30Z 1928 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@GilaMonstrum Noumena Analysis
Noumena Analysis posts on X about $vktx, $pfe, $mtsr, $lly the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +20,264%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +167%
Mentions: X #
- X Week XX +267%
- X Month XX +26%
- X Months XX -XX%
- X Year XXX +331%
Followers: XXXXX #
- X Week XXXXX +2.10%
- X Month XXXXX +5.90%
- X Months XXXXX +53%
- X Year XXXXX +221%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks finance
Social topic influence $vktx #1, $pfe, $mtsr #4, $lly, weight loss #853, rates #675, $nvo, over the, ans, investment
Top assets mentioned Viking Therapeutics, Inc (VKTX) Pfizer, Inc. (PFE) Metsera, Inc. Common Stock (MTSR) Eli Lilly and Company (LLY) Novo-Nordisk (NVO) AltLayer (ALT)
Top Social Posts #
Top posts by engagements in the last XX hours
"@bioinvestor24 $pfe is up $mtsr is up $vktx is down"
X Link @GilaMonstrum 2025-09-30T14:13Z 1895 followers, XXX engagements
"@Doctor_Salomon @LNG_Investor_ My base case: the XX mg arm is at least non-inferior to TZP on weight loss with better safety given the slow titration (starting at XXX mg). I expect the XXXX mg arm to outperform TZP XX mg on both weight loss and safety"
X Link @GilaMonstrum 2025-10-19T17:22Z 1928 followers, XXX engagements
"@bioinvestor24 I just cant get over the fact that $PFE said they reviewed this data and felt "comfortable". It practically screams shady how can they feel confortable to go against $LLY ans $NVO with this"
X Link @GilaMonstrum 2025-09-30T14:11Z 1902 followers, 4660 engagements
"How would $LLY tirzepatide compare with $VKTX sc VK2735 if both are titrated the same To answer this question I built a PK/PD model using the methodology briefly described below: X. Simulate single dose PK for each drug from published parameters (T1/2 and Tmax are reported in the literature/ corporate decks. F=80% for TZP I assumed the same for VK 2735). X. Convert plasma profiles to cumulative exposure (AUC) using the trapezoidal rule. X. Plot AUC to weight loss data from SURMOUNT-1 and VENTURE. X. Fit an individual Hill model for VK and TZP with an assumed Emax of XX% for both drugs."
X Link @GilaMonstrum 2025-10-19T16:38Z 1928 followers, 12.4K engagements
"I understand you want to protect your investment but highlighting $VKTX oral VK 2735 d/c while overlooking $ALT challenging obesity d/c rates is a bit funny tbh. VK2735 has oral and sc forms the higher d/c occurred in the P2 oral trial. Pemvis real competitor would be sc VK2735 so.yeah"
X Link @GilaMonstrum 2025-10-20T04:54Z 1928 followers, 1015 engagements
"@GodSaveCharles "Has yet surpassed" as in "to date". I did not make any assumptions on future trials I guess Novo already made that assumption"
X Link @GilaMonstrum 2025-10-20T06:31Z 1928 followers, XXX engagements
"@bioinvestor24 Clinically it seems to be similar to $LLY tirzepatide but the studies are too short (4 weeks). I wasn't impressed by their P2 data vs semaglutide X mg in diabetics. Maybe it is wishful thinking but I am starting to see a pattern here:"
X Link @GilaMonstrum 2025-06-02T19:45Z 1925 followers, 4480 engagements
"$MTSR $PFE Finally released the Phase 2b VESPER X and VESPER X results and frankly their PR is confusing and selectively framed. I have a headache after reading it. $VKTX BL take notes this is a masterclass in how to spin your data. Vesper X had X arms (MET-097i XXX mg XXX mg XXX mg and XXX mg) QW without titration. The efficacy they reported is pbo-adjusted and they withheld the actual placebo WL data. This is a huge red flag given that in their previous trials the placebo arm gains weight (uniquely as far as Ive seen - see pic). By hiding placebo here they can inflate the headline and claim"
X Link @GilaMonstrum 2025-09-30T06:17Z 1930 followers, 15.3K engagements
"@Doctor_Salomon @LNG_Investor_ I haven't seen data as good as tzp in Surmount X with anything else so far"
X Link @GilaMonstrum 2025-10-19T17:06Z 1930 followers, XXX engagements
"Has anyone seen the $MTSR discontinuation rates for any of their drugs $VKTX"
X Link @GilaMonstrum 2025-09-25T12:26Z 1928 followers, 4589 engagements
""At XX weeks in MOMENTUM mean weight loss reached 1015.6 % without titration and with sub-5 % discontinuations at mid-dose which is extremely impressive for a compound with NO dose escalation" How can you claim sub X% discontinuations with mid doses in Momentum when the XXX mg dose showed a XXXX% d/c and the XXX mg dose showed d/c of XXXX% Also if you include the weight loss of XXXX% for the XXX mg (titrated) dose make sure you also include the d/c rate for that dose (which was a staggering 42.3%). Otherwise it is a WL between XXXX% and XXXX% (8.1% and X% PBO adjusted) at XX weeks with d/c"
X Link @GilaMonstrum 2025-10-20T07:30Z 1928 followers, XXX engagements